Targeted therapy for advanced salivary gland carcinoma based on molecular profiling: results from MyPathway, a phase IIa multiple basket study.

•Pertuzumab + trastuzumab produced a response in 60% (9/15) of patients with HER2-amplified/overexpressing salivary cancer.•Stable disease was observed in a patient with HER2-mutated salivary cancer treated with pertuzumab + trastuzumab.•Vismodegib, vemurafenib, and atezolizumab produced responses in salivary tumors with matched genomic alterations.•Safety for each treatment was consistent with previously reported safety profiles.•Results support use of molecular profiling to identify effective chemotherapy-free targeted treatments for salivary cancers.